ClinicalTrials.gg
CompletedNCT06930664Updated Dec 15, 2025

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

A Phase 1 interventional study of Sotatercept and Sotatercept Autoinjector in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to female participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Study summary

The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a body weight between 75 and 100 kg, inclusive
  • Is assigned female sex at birth and is a participant of nonchildbearing potential (PONCBP) defined as one of the following:

    • Premenarchal
    • Premenopausal with documented hysterectomy and/or bilateral salpingectomy
    • Medical cause of permanent infertility (eg, Müllerian agenesis, androgen insensitivity)

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of opportunistic infection (eg, invasive candidiasis or pneumocystis pneumonia)
  • Has had a serious local infection (eg, cellulitis, abscess) or systemic infection (eg, septicemia) within 3 months prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Active comparator
    High Dose Subcutaneous Injection

    Participants will receive a single subcutaneous high dose of sotatercept administered via syringe.

    Biological: Sotatercept

  • Experimental
    High Dose Subcutaneous Autoinjector

    Participants will receive a single subcutaneous high dose of sotatercept administered via autoinjector.

    Biological: Sotatercept Autoinjector

  • Experimental
    Low Dose Subcutaneous Autoinjector

    Participants will receive a single subcutaneous low dose of sotatercept administered via autoinjector.

    Biological: Sotatercept Autoinjector

Interventions

  • BiologicalSotatercept

    Subcutaneous Injection

    Also known as: MK-7962, ActRIIA-IgG1Fc, ACE-011

  • Subcutaneous Auto Injection

    Also known as: MK-7962, ActRIIA-IgGIFc, ACE-011

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Sotatercept at High Dose

    Blood samples will be collected to determine the AUC0-inf of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose)

  2. Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Sotatercept at High Dose

    Blood samples will be collected to determine the AUC0-last of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  3. Maximum Observed Concentration (Cmax) of Sotatercept at High Dose

    Blood samples will be collected to determine the Cmax of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

Secondary outcomes

  1. Time of the Maximum Observed Concentration (Tmax) of Sotatercept High Dose

    Blood samples will be collected to determine the Tmax of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  2. Apparent Terminal Elimination Half-Life (t1/2) of Sotatercept at High Dose

    Blood samples will be collected to determine the t1/2 of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  3. Apparent Total Plasma Clearance (CL/F) of Sotatercept at High Dose

    Blood samples will be collected to determine the CL/F of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  4. Apparent Volume of Distribution During Terminal Elimination Phase (Vz/F) of Sotatercept at High Dose

    Blood samples will be collected to determine the Vz/F of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  5. Cmax of Sotatercept Low Dose

    Blood samples will be collected to determine the Cmax of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  6. Tmax of Sotatercept at Low Dose

    Blood samples will be collected to determine the Tmax of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  7. AUC0-inf of Sotatercept at Low Dose

    Blood samples will be collected to determine the AUC0-inf of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  8. AUC0-last of Sotatercept at Low Dose

    Blood samples will be collected to determine the AUC0-last of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  9. t1/2 of Sotatercept at Low Dose

    Blood samples will be collected to determine the t1/2 of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  10. CL/F of Sotatercept at Low Dose

    Blood samples will be collected to determine the CL/F of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  11. Vz/F of Sotatercept at Low Dose

    Blood samples will be collected to determine the Vz/F of sotatercept in plasma.

    Time frame: Predose and at designated timepoints (up to approximately 120 days postdose

  12. Number of Participants who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 120 days

  13. Number of Participants who Discontinued the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 120 days

07

Study locations

4 sites
  • Anaheim Clinical Trials ( Site 0007)
    Anaheim, California 92801, United States
  • Advanced Pharma CR, LLC ( Site 0005)
    Miami, Florida 33147, United States
  • QPS-MRA, LLC ( Site 0004)
    South Miami, Florida 33143, United States
  • Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0003)
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Nov 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
May 16, 2025
Primary completionActual
Nov 11, 2025
CompletionActual
Nov 25, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06930664
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
May 16, 2025
Primary completion
Nov 11, 2025
Completion
Nov 25, 2025
Last update
Dec 15, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion